Investigational Drug Information for Telaglenastat
✉ Email this page to a colleague
What is the drug development status for Telaglenastat?
Telaglenastat is an investigational drug.
There have been 16 clinical trials for Telaglenastat.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 14th 2018.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and Prostate Cancer Foundation.
There are seventeen US patents protecting this investigational drug and one hundred and seventy-six international patents.
Summary for Telaglenastat
| US Patents | 17 |
| International Patents | 176 |
| US Patent Applications | 76 |
| WIPO Patent Applications | 31 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2018-05-14) |
| Vendors | 55 |
Recent Clinical Trials for Telaglenastat
| Title | Sponsor | Phase |
|---|---|---|
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | Calithera Biosciences, Inc | Phase 2 |
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | National Cancer Institute (NCI) | Phase 2 |
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | Washington University School of Medicine | Phase 2 |
Clinical Trial Summary for Telaglenastat
Top disease conditions for Telaglenastat
Top clinical trial sponsors for Telaglenastat
US Patents for Telaglenastat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Telaglenastat | ⤷ Subscribe | Combination therapy with glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | ⤷ Subscribe |
| Telaglenastat | ⤷ Subscribe | Compositions and methods of treating cancer harboring PIKC3A mutations | Case Western Reserve University (Cleveland, OH) | ⤷ Subscribe |
| Telaglenastat | ⤷ Subscribe | Combination therapy with glutaminase inhibitors and immuno-oncology agents | Calithera Biosciences, Inc. (South San Francisco, CA) | ⤷ Subscribe |
| Telaglenastat | ⤷ Subscribe | Combination therapy with glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Telaglenastat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Telaglenastat | China | CN109982703 | 2036-08-25 | ⤷ Subscribe |
| Telaglenastat | European Patent Office | EP3503893 | 2036-08-25 | ⤷ Subscribe |
| Telaglenastat | Japan | JP2019524852 | 2036-08-25 | ⤷ Subscribe |
| Telaglenastat | World Intellectual Property Organization (WIPO) | WO2018039441 | 2036-08-25 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
